US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Skye Bioscience Inc.

1.57

+0.13509.41%

Pre-market: 1.40-0.1700-10.83%05:22 EDT

Volume:568.35K

Turnover:848.85K

Market Cap:48.63M

PE:-2.15

High:1.58

Open:1.40

Low:1.36

Close:1.44

Loading ...

Overview Company News Filings

Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Calendar of U.S. Earnings Expected in the Week Ahead

Skye Bioscience Inc expected to post a loss of 28 cents a share - Earnings Preview

William Blair Initiates Skye Bioscience at Outperform

MT Newswires Live

Skye Bioscience Initiated at Outperform by William Blair

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Skye Bioscience initiated with an Outperform at William Blair

Skye Bioscience to Participate in SXSW Session on Obesity

We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely

Simply Wall St.

Skye Bioscience to Present at TD Cowen Health Care Conference

Craig-Hallum Reaffirms Their Buy Rating on Skye Bioscience (SKYE)

Skye Bioscience Announces Participation in February Conferences

Skye Bioscience Provides 2025 Look Ahead and Year in Review

Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond

Skye Bioscience (SKYE) Has a New Rating from Craig-Hallum

BRIEF-Skye Bioscience Surpasses 50% Patient Enrollment In Phase 2 Obesity Study Of Differentiated CB1 Inhibitor

Skye Bioscience Inc - Expects Interim Data for Cbeyond Phase 2 Trial in Q2 2025

THOMSON REUTERS

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

THOMSON REUTERS

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience Inc reports results for the quarter ended in September 30 - Earnings Summary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SKYE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":1.57,"timestamp":1745265600000,"preClose":1.435,"halted":0,"volume":568349,"hourTrading":{"tag":"盘前","latestPrice":1.4,"preClose":1.57,"latestTime":"05:22 EDT","volume":141,"amount":199.03999919999998,"timestamp":1745313773843},"delay":0,"floatShares":17255988,"shares":30974558,"eps":-0.73,"marketStatus":"Pre-Mkt","change":0.135,"latestTime":"04-22 07:27:39 EDT","open":1.4,"high":1.58,"low":1.36,"amount":848849.0668800999,"amplitude":0.15331,"askPrice":1.7,"askSize":100,"bidPrice":1.42,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.73,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":1.57,"preHourTrading":{"tag":"盘前","latestPrice":1.4,"preClose":1.57,"latestTime":"05:22 EDT","volume":141,"amount":199.03999919999998,"timestamp":1745313773843},"postHourTrading":{"tag":"盘后","latestPrice":1.55,"preClose":1.57,"latestTime":"19:58 EDT","volume":10144,"amount":15519.9858,"timestamp":1745279904436},"volumeRatio":0.09631375995537646,"impliedVol":2.3324,"impliedVolPercentile":0.7489},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":17255988,"roa":"-44.56%","roe":"-80.48%","lyrEps":-0.728135,"volumeRatio":0.09631375995537646,"shares":30974558,"dividePrice":0,"high":1.58,"amplitude":0.15331,"preClose":1.435,"low":1.36,"week52Low":1.14,"pbRate":"0.71","week52High":16.01,"institutionHeld":0,"latestPrice":1.57,"eps":-0.73,"divideRate":0,"volume":568349,"delay":0,"ttmEps":-0.73,"open":1.4,"prevYearClose":2.83,"prevWeekClose":1.435,"prevMonthClose":1.59,"prevQuarterClose":1.59,"fiveDayClose":1.41,"twentyDayClose":2.25,"sixtyDayClose":2.61},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521496551","title":"Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496551?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:01","pubTimestamp":1742500860,"startTime":"0","endTime":"0","summary":"-- Enrollment completed in Phase 2a CBeyond trial of CB1 inhibitor,-- Faster-than-expected enrollment enables full top-line Phase 2a data in. late Q3/early Q4 2025, ahead of schedule; interim analysis removed. -- Phase 2a dosing extended to 52 weeks to enhance long-term safety,\"Skye's prime accomplishment in 2024 was the initiation and rapid advancement of its comprehensive Phase 2a clinical study of nimacimab, a novel and differentiated CB1 inhibitor,\" said Punit Dhillon, President & CEO of Skye. \"Maturation of the obesity therapeutics landscape, including expanding clinical evidence, M&A, and licensing, highlights the strategic importance of alternative mechanisms of action with attributes differentiated from incretins. We believe nimacimab's product profile is well-positioned to potentially fulfill critical unmet needs in this rapidly evolving therapeutic area.exceeded the initial target of 120, with data blinded through the. -- Data Safety Monitoring Board reviews completed: Two in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","TM","03160","BK4555","BK4585","BK4588","BK4604","BK4139","BK4099"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRAG","NKE","NKTX","OUST","LEN","DRI","JEF","CBUS","FBRX","DERM","IFRX","MBRX","BRNS","ASO","MGNX","MLKN","RUM","COYA","PL","TELA","SBS","SOWG","SKYE","SPRY","BCAB","BLRX","FLUX","ACRV","THRD","ALUR","CMC","CURV","TITN","BBNX","JKS","GDEV","MNSO","LVTX","MREO","KLC","CDLR","SLS","CELC","TH","LPTX","WOR","RLMD","PAYX"],"gpt_icon":1},{"id":"2520934058","title":"Skye Bioscience Inc  expected to post a loss of 28 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2520934058","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520934058?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:25","pubTimestamp":1742329508,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc  expected to post a loss of28cents a share - Earnings Preview Skye Bioscience Inc SKYE.OQ SKYE.O is expected to show no change in quarterly revenue when it reports  results on Marc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL8N3Q123P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2514132964","title":"William Blair Initiates Skye Bioscience at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2514132964","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514132964?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:02","pubTimestamp":1740747730,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE) has an average rating of buy and mean price target of $17.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SKYE"],"gpt_icon":0},{"id":"2514325421","title":"Skye Bioscience Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514325421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514325421?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:27","pubTimestamp":1740745620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SKYE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 07:27 ET (12:27 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0},{"id":"2514235141","title":"Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514235141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514235141?lang=en_us&edition=fundamental","pubTime":"2025-02-28 07:00","pubTimestamp":1740697258,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nTUA4HBRZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2514359840","title":"Skye Bioscience initiated with an Outperform at William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2514359840","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514359840?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:20","pubTimestamp":1740694838,"startTime":"0","endTime":"0","summary":"William Blair initiated coverage of Skye Bioscience (SKYE) with an Outperform rating. Published first on TheFly – the ultimate source for real-time...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/skye-bioscience-initiated-with-an-outperform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/skye-bioscience-initiated-with-an-outperform-at-william-blair?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2513119740","title":"Skye Bioscience to Participate in SXSW Session on Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2513119740","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513119740?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:00","pubTimestamp":1740398400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb. 24, 2025  -- Skye Bioscience, Inc.  , a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.SXSW Conference Panel Session: \"Weighing in on Weight Loss Medicine\". SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive meaningful conversations. Its dedicated tracks on health and medtech spotlight groundbreaking advancements and transformative ideas shaping the future of life sciences.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-participate-sxsw-session-120000642.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2513271803","title":"We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2513271803","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513271803?lang=en_us&edition=fundamental","pubTime":"2025-02-22 20:15","pubTimestamp":1740226502,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So, the natural question for Skye Bioscience  shareholders is whether they should be concerned by its rate of cash burn. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.When Might Skye Bioscience Run Out Of Money?Since it has a market capitalisation of US$90m, Skye Bioscience's US$22m in cash burn equates to about 25% of its market value. That's not insignificant, and if the company had to sell enough shares","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-hopeful-skye-bioscience-nasdaq-121502560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU2095319765.USD","PSQ","SKYE","IE00B3QW5Z07.USD","BK4585","USAW.SI","QID","BK4112","LU2210149790.SGD","TQQQ","NDAQ","TSYW.SI","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","NVIW.SI","BK4588","SQQQ","MNQmain","IE00B64PRP62.GBP",".IXIC","QLD","NQmain","USJW.SI","QQQ"],"gpt_icon":0},{"id":"2512446267","title":"Skye Bioscience to Present at TD Cowen Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2512446267","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512446267?lang=en_us&edition=fundamental","pubTime":"2025-02-20 20:00","pubTimestamp":1740052800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Calif., Feb. 20, 2025  -- Skye Bioscience, Inc.  , a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that Punit Dhillon, Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the TD Cowen 45th Annual Health Care Conference.A live and archived webcast will be accessible on Skye’s website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-present-td-cowen-120000755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4139","BK4127","COWN","BK4207","SKYE","TD","BK4585"],"gpt_icon":0},{"id":"2509279858","title":"Craig-Hallum Reaffirms Their Buy Rating on Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509279858","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509279858?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:50","pubTimestamp":1738849810,"startTime":"0","endTime":"0","summary":"Craig-Hallum analyst Albert Lowe maintained a Buy rating on Skye Bioscience (SKYE – Research Report) today. The company’s shares closed yesterday a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-skye-bioscience-skye?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-skye-bioscience-skye?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE"],"gpt_icon":0},{"id":"2508654458","title":"Skye Bioscience Announces Participation in February Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2508654458","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508654458?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:00","pubTimestamp":1738670400,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb. 04, 2025  -- Skye Bioscience, Inc.  , a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following investor conferences:. BIO CEO & Investor ConferenceNew YorkPanel: Obesity: Next Medicines with ImpactMonday, February 10, 2025, 11:00 AM - 11:50 AM ET. Oppenheimer 35th Healthcare Life Sciences Conference VirtualCorporate overview Wednesday, February 12th, 2025, at 12:00 PM - 12:30 PM ETA live and archived webcast will be accessible on Skye’s website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-announces-participation-february-120000000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2503630359","title":"Skye Bioscience Provides 2025 Look Ahead and Year in Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2503630359","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503630359?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769600,"startTime":"0","endTime":"0","summary":"Expected Phase 2 obesity data in Q2 2025 and Q4 2025 will shape clinical potential and development path of distinctive CB1 inhibitor. SAN DIEGO, Jan. 13, 2025  -- Skye Bioscience, Inc.  , a clinical-stage biopharmaceutical company developing new therapeutic pathways for metabolic health, enters 2025 positioned to announce Phase 2 data for nimacimab, a non-incretin mechanism and first-in-class, peripherally-restricted CB1 inhibitor antibody with the potential to enhance important facets of obesity treatment while achieving significant weight loss. Skye’s goal in 2025 is to achieve clinical milestones and new scientific insights related to the unique effects and metabolic mechanisms of peripheral CB1 inhibition.“The understanding of mechanisms and opportunities to best treat obesity and overweight is still early in its evolution. There is potential to offer clinicians and patients more choices to address the unmet needs of incretin therapeutics, which include unresponsiveness to these dr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-provides-2025-look-120000144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2483373915","title":"Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond","url":"https://stock-news.laohu8.com/highlight/detail?id=2483373915","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483373915?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:45","pubTimestamp":1731674710,"startTime":"0","endTime":"0","summary":"Skye Bioscience  announced that it has achieved more than 50% of targeted patient enrollment for its CBeyond Phase 2 clinical trial assessing nimacimab, a differentiated CB1 inhibitor, in patients with overweight or obesity. Skye expects to report interim data for the CBeyond Phase 2 clinical trial in Q2 2025 after this initial set of enrolled patients has completed the 26-week treatment period. “We are grateful for the amazing motivation and responsiveness shown by our study participants and clinical investigators in the assessment of this first-in-class drug candidate for weight loss. The current pace of patient enrollment may also shorten our timeline to topline data next year. We will provide a further update after reaching full enrollment,” said Puneet Arora, MD, Skye’s Chief Medical Officer. “This is a rigorous clinical trial evaluating multiple important parameters. We look forward to advancing nimacimab through this program and getting this Phase 2 data next year.”Skye Bioscien","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.2OcvspZzvCzzeMPm.N5LA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.2OcvspZzvCzzeMPm.N5LA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/373719bd4f9106065622fdb013c92607"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/skye-bioscience-achieved-more-50-124510873.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-achieved-more-50-124510873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2483280574","title":"Skye Bioscience (SKYE) Has a New Rating from Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2483280574","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483280574?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:57","pubTimestamp":1731592639,"startTime":"0","endTime":"0","summary":"Skye Bioscience (SKYE – Research Report) received a Buy rating and price target from Craig-Hallum analyst Albert Lowe today. The company’s shares c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-has-a-new-rating-from-craig-hallum?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-has-a-new-rating-from-craig-hallum?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SKYE"],"gpt_icon":0},{"id":"2483871310","title":"BRIEF-Skye Bioscience Surpasses 50% Patient Enrollment In Phase 2 Obesity Study Of Differentiated CB1 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2483871310","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483871310?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:23","pubTimestamp":1731586993,"startTime":"0","endTime":"0","summary":"Nov 14  - Skye Bioscience Inc   :   * SKYE BIOSCIENCE SURPASSES 50% PATIENT ENROLLMENT IN PHASE 2 OBESITY STUDY OF DIFFERENTIATED CB1 INHIBITOR   * SKYE BIOSCIENCE INC - EXPECTS INTERIM DATA FOR CBEYOND PHASE 2 TRIAL IN Q2 2025Source text:   Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2483876935","title":"Skye Bioscience Inc - Expects Interim Data for Cbeyond Phase 2 Trial in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876935?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUAB8LT5Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2483876550","title":"Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876550?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUAB8LT5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2483808720","title":"Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2483808720","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483808720?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov. 14, 2024  -- Skye Bioscience, Inc.  , a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it has achieved more than 50% of targeted patient enrollment for its CBeyondPhase 2 clinical trial assessing nimacimab, a differentiated CB1 inhibitor, in patients with overweight or obesity. Skye expects to report interim data for the CBeyondPhase 2 clinical trial in Q2 2025 after this initial set of enrolled patients has completed the 26-week treatment period.“We are grateful for the amazing motivation and responsiveness shown by our study participants and clinical investigators in the assessment of this first-in-class drug candidate for weight loss. The current pace of patient enrollment may also shorten our timeline to topline data next year. We will provide a further update after reaching full enrollment,” said Puneet Arora, MD, Skye’s Chief Medical Officer. “This is a rigorous clinical trial evalu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_XiVOFHLzP3yCg0Chjy5SQ--~B/aD02NDA7dz0xMzYxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/bfe20810bd2d446dc8a9c2978a5f4047","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_XiVOFHLzP3yCg0Chjy5SQ--~B/aD02NDA7dz0xMzYxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/bfe20810bd2d446dc8a9c2978a5f4047"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/skye-bioscience-surpasses-50-patient-120000058.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2481118641","title":"Skye Bioscience Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481118641","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481118641?lang=en_us&edition=fundamental","pubTime":"2024-11-08 13:11","pubTimestamp":1731042703,"startTime":"0","endTime":"0","summary":"* Skye Bioscience Inc    reported a quarterly adjusted loss of 10 cents per share for the quarter ended September 30.  The mean expectation of six analysts for the quarter was for a loss of 25 cents p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24},{"market":"US","date":"2024-11-07","symbol":"SKYE","fiscalQuarterEnding":"2024/09","expectedEps":-0.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-08-09","symbol":"SKYE","fiscalQuarterEnding":"2024/06","expectedEps":-0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2024-05-10","symbol":"SKYE","fiscalQuarterEnding":"2024/03","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"post","actualEps":-0.18},{"market":"US","date":"2024-03-21","symbol":"SKYE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710993600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.7143,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7143,"analysts":7,"updateTime":1740888000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2025-04-17","current":-1.842119,"percent":0.957983,"low":-12.94129,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"high":-1.399078,"avg":-5.125839,"sd":2.482527,"marketCap":48939801},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801}],"updateTime":1745308247625}}}